ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

15 Health Benefits of Chia Seeds, According to Science

Natural Remedies for the Prevention of Dry Eyes

Tangerine Oil: A Citrusy Essential Oil With Well-Rounded Uses

Magnesium Deficiency Raises Your Risk of Many Chronic Ailments

Resveratrol supplementation improves arterial stiffness in type 2 diabetics

What Makes Spanish Marjoram Oil Special?

CoQ10's Potential Capabilities for Your Health

How Can Melatonin Benefit You?

Cloves: Boost Your Immune System the Sweet and Spicy Way

8 Chia Seed Recipes

 
Print Page
Email Article

Report on Clinical Study of Synvisc for Treatment of Osteoarthritis

  [ 1 vote ]   [ Discuss This Article ]
By ArthritisSupport Staff • www.ProHealth.com • February 28, 2000


News Release

SUMMARY: 12-month results of a clinical study of Synvisc® yielded uniformly positive and statistically significant results in favor of using it as an arthritis treatment. Report on Clinical Study of Synvisc for Treatment of Osteoarthritis. Study findings showed Synvisc treatment results in long term improvements in pain, function and quality of life.

ABSTRACT: RIDGEFIELD, N.J., Feb. 28 /PRNewswire/ -- Today Biomatrix, Inc. reported that data from a randomized controlled clinical trial analyzing the clinical effectiveness and cost effectiveness of the use of Synvisc® for the management of osteoarthritis of the knee were presented during the annual Canadian Rheumatology Association's Annual Meeting held in Lake Louise, Canada. Synvisc® is the company's novel elastoviscous (a physical device/fluid that acts as a shock absorber and lubricant) therapeutic device for the treatment of osteoarthritis of the knee. This recently completed trial was designed, managed and reported by an independent academic steering committee of international opinion leaders in compliance with published guidelines for pharmacoeconomic studies. Fourteen clinical investigators, specialists in rheumatology or orthopedics, conducted the study over the past two years with patients from all across Canada.

Dr. George Torrance, Ph.D., Professor Emeritus, McMaster University and Innovus Research Inc. of Burlington, Ontario, and the principal economic investigator of the academic Steering Committee for this trial, commented, "We are delighted with all aspects of this study. The design was state of the art, the sites did a terrific job of providing high quality data, the analysis was rigorous to the highest standards, and the results were uniformly positive and statistically significant in favor of the treatment arm which included Synvisc. We look forward to the release of full trial results from this landmark study in a leading peer-reviewed journal."

Dr. Endre Balazs, M.D., Biomatrix' chief executive officer and chief scientific officer, stated, "This study represents an important milestone in the development of treatment for osteoarthritis (OA) using viscosupplementation (the therapeutic procedure that restores the physical properties of diseased synovial fluid with an elastoviscous fluid like Synvisc) with Synvisc. It provides a straightforward comparison of treatment paradigms for knee OA with and without Synvisc, and demonstrates unequivocally that Synvisc treatment results in long term improvements in pain, function and quality of life. Furthermore, the data demonstrate that Synvisc provides health care value, a critical step in the adoption of any new technology."

In conclusion, Dr. Balazs said, "We are pleased with the steering committee's outstanding efforts in carrying out this detailed and comprehensive evaluation of the use of Synvisc for the management of osteoarthritis of the knee. We believe this study will be beneficial in positioning viscosupplementation with Synvisc as a standard therapy within the treatment guidelines for OA of the knee, and in supporting our reimbursement initiatives worldwide."

Source: Biomatrix, Inc.



Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ Energy NADH™ 12.5mg Ultra ATP+, Double Strength


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health

Natural Remedies

Looking for Energy? Turn to Plants. Looking for Energy? Turn to Plants.
Prepare Yourself for Cold & Flu Season Prepare Yourself for Cold & Flu Season
How Glutathione Can Save Your Life How Glutathione Can Save Your Life
Are You Obtaining the Proper Enzymes? Are You Obtaining the Proper Enzymes?
The New Dual Activation Pain Relief Cream The New Dual Activation Pain Relief Cream

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map